Ascorbic acid
As of the edition of 20 October 2026, Ascorbic acid is a small molecule: marketed, first approved in 1952 (ES).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1987
- Kind
- Small molecule
- Brand name
- M.V.I.-12 Adult
- First approved
- 1 July 1952 (ES)
- Approvals on record
- 38 in 5 regions
- Holder of the most recent approval
- B. Braun Medical; 16 holders in all
- Registered trials
- 194, 41 stopped early
- Disease areas
- Cancer; Digestive system; Heart and blood vessels; Infections; Blood and lymph; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 31 | 18 | 4 | 2 |
| Phase 1 | 40 | 17 | 7 | 13 |
| Phase 2 | 69 | 30 | 9 | 19 |
| Phase 3 | 26 | 14 | 2 | 4 |
| Phase 4 | 28 | 17 | 3 | 3 |
| All trials | 194 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bayer | Applicant | 1970 to now |
| Baxter Healthcare | Later holder | 1987 to now |
| Reckitt Benckiser | Later holder | 2009 to now |
| McGuff Pharmaceuticals | Applicant and Lead sponsor of trials | 2015 to now |
| B. Braun Medical | Later holder | 2024 to now |